Cascadian Therapeutics Inc., of Seattle, said that following a meeting with the FDA and discussions with their external steering committee, it has amended the HER2CLIMB phase II trial of tucatinib (also known as ONT-380) by increasing the sample size so that, if successful, the trial could serve as a single pivotal study to support registration.